Work

A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.2013

Authors: Lakshmi Nayak, John L. Hays, Alona Muzikansky, Sarah C. Gaffey, Khanh Tu Do, Vinay K. Puduvalli, Eudocia Quant Lee, Mikael L. Rinne, Andrew David Norden, Rameen Beroukhim, Patrick Y. Wen, L. Austin Doyle, Helen X. Chen, Geoffrey Shapiro, David A. Reardon

Institutions: Dana-Farber Cancer Institute, The Ohio State University Wexner Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, National Cancer Institute, Harvard University, Dana-Farber/Harvard Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2518309255

Cites:

Cited by: 5

Related to: 10